摘要
目的了解缺血性脑卒中患者住院期间二级预防药物的应用情况,为改进缺血性脑卒中二级预防工作提供依据。方法回顾性调查899例缺血性脑卒中患者住院期间二级预防药物的服药率。结果在899例缺血性脑卒中患者中,合并高血压者有632例,合并糖尿病者有220例,既合并有高血压又合并糖尿病者有177例。入选的899例患者中,服用抗血小板药物者占91.9%(826例),在短暂性脑缺血发作组和脑梗死组间差异有统计学意义(P<0.01);服用调脂药物者占77.2%(694例),在短暂性脑缺血发作组和脑梗死组间差异无统计学意义;632例缺血性脑卒中合并高血压患者中服用降压药者占95.4%(603例);220例缺血性脑卒中合并糖尿病患者中服用降糖药者(包括使用胰岛素)占84.5%(186例);177例既合并有高血压又合并有糖尿病的脑卒中患者中均用药者占83.1%(147例)。结论住院期间脑梗死患者抗栓药物服用率较短暂性脑缺血发作高,缺血性脑卒中二级预防用药尚不令人满意,临床医生应对脑卒中的二级预防治疗给予重视。
Objective To investigate the status of taking medicine during hospitalization in secondary prevention of ischemic stroke and to provide evidence for improving the second prevention.Methods 899 ischemic stroke patients during hospitalization were followed up to study the status of the using medication in secondary prevention of stroke.Results Of 899 patients of ischemic stroke,632 patients complicated with hypertension,220 patients complicated with diabetes,and 177 patients complicated with both hypertension and diabetes.In all followed up patients,the proportion of using antiplatelet treatment was 91.9%(826 cases),and there was statistical difference between transient ischemic attack(TIA) group and cerebral infarct group.The rate of using lipid lowering agents was 77.2%(694 cases),and no difference is found between the two groups.In patients complicated with hypertension,the proportion of antihypertensive treatment was 95.4%(603 cases),and in complicated with diabetes patients,the rate of accepting treatment was 84.5%(186cases).Of complicated with hypertension and diabetic patients,taking treating medicine was 83.1%.Conclusions The rate of taking antiplatelet agents in cerebral infarct was higher than transient ischemic attack,The status of the using medication during hospitalization in secondary prevention of ischemic stroke were not optimistic,doctors should pay attention to the secondary prevention of ischemic stroke.
出处
《中华脑血管病杂志(电子版)》
2012年第1期12-15,共4页
Chinese Journal of Cerebrovascular Diseases(Electronic Edition)
关键词
缺血性脑卒中
二级预防
药物
Ischemic cerebrovascular stroke
Secondary prevention
Medication